The Liberty surgical robot platform. [Image courtesy of Microbot Medical]
Microbot Medical (Nasdaq:MBOT) announced today that it partnered with a third-party logistics company to support its Liberty launch.
The company enlisted the undisclosed logistics firm as it prepares to roll out its Liberty endovascular robotic system in the coming weeks. It expects to initiate a limited launch in the fourth quarter of 2025, with a broader launch planned for April 2026.
Liberty became the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures last month. Microbot designed the Liberty robot to democratize endovascular interventional procedures. The company says it’s the world’s first single-use, fully disposable robotic system for those procedures.
Microbot also boosted its commercialization efforts with significant funding. The company exercised certain investment options worth up to $92.2 million last week to support the Liberty rollout.
According to Microbot, the logistics company it partnered with is a fully compliant and integrated fulfillment solutions provider specializing in the medical device industry. This would allow Microbot to leverage its proximity to key markets and provide effective and efficient order processing and the ability to maintain inventory to meet expected demand from a strategically located, climate-controlled warehouse.
“As we continue to establish the infrastructure to support the commercial launch of Liberty following FDA clearance, we believe that having an established logistics provider with deep medtech expertise puts us in a stronger position to achieve our go-to-market initiatives more efficiently,” said Michal Ahuvia, director of operations.
